Key players are focused on developing recombinant human insulin instead of animal-based insulin, owing to increasing demand for human insulin in the treatment of diabetes. Human recombinant insulin has a faster onset of action and lower immunogenicity than pork or beef insulin. Currently human recombinant insulin is gaining significant traction with the development of biosimilars analogue of human insulin.
Figure 2.Global Human Recombinant Insulin Market Share (%), by Region, 2022
Various government and private research organizations are engaged in research and development activities for developing advanced treatment in diabetes care to increase the effectiveness of human insulin, reduce diabetes burden, and minimize the risk of diabetes associated disorders such as diabetes-associated blindness, kidney disease, heart attacks, strokes or limb loss. For instance, on April 25, 2022, The American Diabetes Association (ADA) announced the opening of a new nomination window for the Pathway to Stop Diabetes research grants in 2022. The ADA is looking for scientists for research and development for diabetes by awarding two five-to-seven-year grants, the ADA will provide funding up to US$ 1.625 million over either five or seven years, which allows diabetes researchers the resources and protected time to pursue innovative research.
Key Players
Major players operating in the global human recombinant insulin market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd., and Dongbao Enterprise Group Co., Ltd.
Human Recombinant Insulin Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients